1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Ambu A/S
  6. Summary
    AMBU B   DK0060946788

AMBU A/S

(AMBU B)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-08-12 am EDT
77.00 DKK   -1.51%
08/04TRANSCRIPT : Ambu A/S, Q3 2022 Earnings Call, Aug 04, 2022
CI
08/03Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction program. Full-year 2021/22 guidance revised
GL
08/03Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction program. Full-year 2021/22 guidance revised
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
08/08/2022 08/09/2022 08/10/2022 08/11/2022 08/12/2022 Date
73(c) 72.88(c) 72.4(c) 78.18(c) 77(c) Last
1 676 410 1 128 622 2 386 860 2 141 794 821 528 Volume
+3.63% -0.16% -0.66% +7.98% -1.51% Change
More quotes
Estimated financial data (e)
Sales 2022 4 395 M 606 M 606 M
Net income 2022 310 M 42,7 M 42,7 M
Net Debt 2022 1 320 M 182 M 182 M
P/E ratio 2022 64,1x
Yield 2022 0,36%
Sales 2023 5 314 M 732 M 732 M
Net income 2023 388 M 53,4 M 53,4 M
Net Debt 2023 1 302 M 180 M 180 M
P/E ratio 2023 51,2x
Yield 2023 0,51%
Capitalization 19 564 M 2 696 M 2 696 M
EV / Sales 2022 4,75x
EV / Sales 2023 3,93x
Nbr of Employees 5 000
Free-Float 65,7%
More Financials
Company
Ambu A/S is specialized in the design, production and marketing of medical supplies. Net sales break down by family of products as follows: - single-use endoscopes (54%); - emergency care and resuscitation devices (24.9%): mechanical ventilation devices (insufflators, laryngeal masks, facial masks and respiratory bags), secretion aspirators, immobilization devices, etc. In addition, the group sells dummies for... 
More about the company
Ratings of Ambu A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about AMBU A/S
08/04TRANSCRIPT : Ambu A/S, Q3 2022 Earnings Call, Aug 04, 2022
CI
08/03Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction..
GL
08/03Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction..
GL
08/03Ambu A/S Revises Earnings Guidance for the Full-Year 2021/2022
CI
07/27AMBU A/S : Q3 aide-mémoire file_download
PU
07/27Ambu Announces FDA Clearance of Fifth-Generation Single-Use Bronchoscope
CI
05/19Ambu Appoints New CEO; Shares Up 9%
MT
05/19Britt Meelby Jensen appointed new CEO of Ambu
GL
05/19Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22
CI
05/19Ambu A/S Announces Chief Executive Officer Changes
CI
05/06European shares suffer worst week in 2 months; tech, retail fall
RE
05/06TRANSCRIPT : Ambu A/S, Q2 2022 Earnings Call, May 06, 2022
CI
05/06AMBU A/S : Press Release
CO
05/06AMBU A/S : Half-year report
CO
05/05Interim report for Q2 2021/22 and the half-year
GL
More news
News in other languages on AMBU A/S
08/04POINT SUR LES FORTES VARIATIONS DU J : Royce n'est plus la Rolls, Ubisoft et Tencent parti..
08/03Ambu A/S révise ses prévisions de bénéfices pour l'ensemble de l'année 2021/2022
07/27Ambu annonce l'autorisation de la FDA pour son bronchoscope à usage unique de cinquième..
05/19Ambu nomme un nouveau PDG ; les actions sont en hausse de 9 %.
05/19Ambu A/S réaffirme ses prévisions de bénéfices pour l'exercice 2021/22
More news
Analyst Recommendations on AMBU A/S
More recommendations
Chart AMBU A/S
Duration : Period :
Ambu A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMBU A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 77,00 DKK
Average target price 85,00 DKK
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Britt Meelby Jensen Chief Executive Officer
Thomas Schmidt Chief Financial Officer
J°rgen Jensen Chairman
Mňns Eskil Barsne Executive VP-Global Research & Development
Henrik AnkjŠr Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
AMBU A/S-55.49%2 696
ABBOTT LABORATORIES-20.79%195 226
MEDTRONIC PLC-8.34%125 988
BECTON, DICKINSON AND COMPANY7.29%75 203
HOYA CORPORATION-14.17%39 624
SARTORIUS STEDIM BIOTECH-20.96%36 037